Psychopharmacopeia.com is a progressive web application aimed at providing clinicians with fast access to psychiatric drug information.
Quickly find indications (including off-label), dosing, side effects, clinically useful pharmacokinetic and pharmacodynamic information, drug-drug interactions, and prescribing pearls for special populations i.e. pregnant, lactating, patients with renal or hepatic impairment, elderly, etc. At last, a virtual Rolodex of psychopharm information, accessible anywhere and across devices.
This site is being updated almost daily. Brexanolone is our most recent addition to the rapidly growing drug database.
Check out our new QT reference page with tables summarizing QT prolongation risk factors, including medication tables for both psych and non-psych meds (with comparison of high vs low risk of QT prolongation of various classes of psych meds).
All drugs in the psychopharm database populate our CYP450 table, organized into substrates, inhibitors, and inducers of the major CYP pathways (1A2, 2D6, 2C9/C19, 3A4).
Converting a patient from one benzodiazepine to another? This benzodiazepine conversion tool shows the equipotent dose of the drug you're converting to, while comparing basic pharmacokinetic and prescribing information side-by-side.
The antipsychotic conversion tool allows for quick calculation of equipotent antipsychotic doses for 20 different antipsychotic medications based on published chlorpromazine equivalents and provides suggested cross-taper schedule for making the switch!
The stimulant dose conversion calculator is still in progress, and so far can convert doses to/from among Ritalin, Adderall, Vyvanse, Dexadrine, and Focalin. Look for updates to this conversion tool soon!
Genetic and Environmental Associations With Autism in a 5-Country Cohort
Posted on Tuesday July 16, 2019
This population-based cohort study uses national registry data from 5 countries to investigate additive genetic, maternal, and environmental effects on autism spectrum disorder diagnosis.
Posted on Tuesday June 25, 2019
This Viewpoint discusses the potential therapeutic utility of methylenedioxy-methamphetamine and psilocybin and outlines mental health care infrastructures that would need to be put in place should these drugs be approved for treatment.
Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression
Posted on Tuesday June 04, 2019
This randomized withdrawal study compares the efficacy of esketamine nasal spray plus an oral antidepressant with an oral antidepressant plus placebo nasal spray in delaying relapse of depressive symptoms in patients with treatment-resistant depression who were in stable remission after treatment with esketamine nasal spray plus an oral antidepressant.
Imaging Study of Cannabinoid 1 Receptor Levels in First-Episode Psychosis
Posted on Tuesday July 02, 2019
This cross-sectional case-control cohort study investigates availability of cannabinoid 1 receptor in patients with first-episode psychosis without the confounds of substance use, antipsychotic medication use, or illness chronicity.
Association of Hormonal Contraception With Depression
Posted on Monday October 31, 2016
This nationwide cohort study investigates whether the use of hormonal contraception is positively associated with subsequent use of antidepressants and a diagnosis of depression among women in Denmark.
Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated March 25 2019 15:25:58. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.